Skip to main content

Table 8 Proteinuria over the study period in patients with a 50% decrease of proteinuria (mg/day)

From: Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

Patient CRF number

Baseline

Entry

Cycle 4

Cycle 6

Cycle 9

9

2,100

6,800

1,800

n.a.

1,782

10

3,600

20,880

10,710

1,572

15,576

13

2,500

3,022

1,073

2,793

 

16

360

1,130

1,240

300

230

19

1,000

2,200

1,700

n.a.

1,000

26

120

5,180

800

700

 

31

1,900

3,920

3,200

1,800

10,800

34

300

3,800

900

1,360

270

35

630

2,000

240

160

480

36

1,680

1,700

770

700

340

39

1,976

n.a.

2,274

2,331

1,058

49

1,700

4,600

2,800

2,900

2,360

50

5,000

11,200

750

2,770

6,401

  1. CRF, case report form.